



**KINEXUS**

## **Kinexus Appoints Chief Executive Officer**

*David W. Turner named CEO and Director*

**PRESS RELEASE - 2002 APRIL 17**

**FOR IMMEDIATE RELEASE APRIL 17, 2002**

**VANCOUVER, British Columbia** – Kinexus Bioinformatics Corporation is pleased to announce the recent appointment of Mr. David W. Turner, as Chief Executive Officer and a member of the Board of Directors. Mr. Turner has over twenty-three years of international experience in the healthcare and technology industries where he successfully managed initial public offerings, acquisitions, and business alliances with multi-conglomerate corporations.

As CEO and Resident Entrepreneur of BIRC Corporation, Mr. Turner is most recently responsible for all aspects of the organization including investing, facilitating and developing service companies and infrastructure that support the development of biotechnology and life sciences in British Columbia, Canada. Prior to BIRC, Mr. Turner was the Regional Manager for Zuellig Pharma, a provider of contract manufacturing, marketing, sales distribution and information services to the health care industry in Asia Pacific with sales of US \$2 billion dollars. At Zuellig Pharma, he was directly responsible for nine markets with sales of US \$900 million and over 1,000 employees. He has also held several senior CEO, CFO and director positions with publicly listed companies and is a chartered accountant by profession.

“I am delighted that David has agreed to join Kinexus,” said Dr. Steven Pelech, President and Chief Scientific Officer. “I am confident his leadership, experience and strength in finance and business development will allow Kinexus to achieve its full potential and look forward to working with him to achieve this goal”.

Kinexus offers biomedical researchers in academia and the pharmaceutical industry the ability to simultaneously track the presence and activation states of hundreds of different protein kinases and other regulatory proteins in cell and tissue specimens using the company's proprietary Kinetworks™ screens. This service provides clients with potential leads for signalling proteins that may ultimately be applied to the advancement of drug discovery, disease diagnosis, and global biomedical research.

**For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at [www.kinexus.ca](http://www.kinexus.ca).**